Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback